|1.||Fiume, Luigi: 5 articles (07/2010 - 06/2004)|
|2.||Di Stefano, Giuseppina: 5 articles (07/2010 - 06/2004)|
|3.||Roggenbuck, Dirk: 3 articles (10/2015 - 10/2009)|
|4.||Lin, Wuu-Jyh: 3 articles (08/2015 - 02/2013)|
|5.||Ariatti, Mario: 3 articles (12/2013 - 01/2012)|
|6.||Singh, Moganavelli: 3 articles (12/2013 - 01/2012)|
|7.||Schreiter, Thomas: 3 articles (10/2011 - 05/2004)|
|8.||Czaja, Albert J: 3 articles (08/2010 - 01/2005)|
|9.||Kratz, Felix: 3 articles (08/2006 - 06/2004)|
|10.||Lanza, Marcella: 3 articles (08/2005 - 06/2004)|
04/01/1998 - "Infection studies further demonstrated that virus adsorption and penetration can be mediated solely by the F protein when the human asialoglycoprotein receptor is present at the surface of host cells."
01/01/2001 - "In contrast to previous suggestions, our data show that the asialoglycoprotein receptor is not required for efficient infection. "
07/01/1997 - "A possible physiological role of the ASGP-R-mediated route of SV infection is discussed."
07/01/1997 - "Furthermore, cleavage of SV-F0 precursor protein into the subunits F1 and F2 was necessary to establish infection via ASGP-R, suggesting a fusion-mediated cell entry after binding of SV-wt to the ASGP-R on host cells. "
07/01/1997 - "We now have investigated this possible alternative route of infection for SV wild-type (SV-wt) strain Fushimi by using a pair of cell lines which differ only with regard to ASGP-R expression. "
|2.||Hepatocellular Carcinoma (Hepatoma)
10/04/2002 - "To study the effects of palmitoylation on ASGP-R activity and function, we generated four types of stably transfected cell lines in SK-Hep-1 hepatoma cells, expressing wild-type, or partially or completely palmitoylation-defective ASGP-Rs containing Cys-to-Ser mutations in either one or both subunits. "
06/03/2014 - "Moreover, we determined that quinonyl galactoside functionalized QDs could optically image the asialoglycoprotein receptors of a hepatoma cell line in a target-specific manner. "
01/01/2014 - "MTX-PL was also used as a hepatoma targeting moiety, because of its specific binding affinity for asialoglycoprotein receptor (ASGPR) overexpressed by human hepatoma HepG2 cells. "
12/01/2013 - "Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma."
09/01/2010 - "The C(60)-pullulan conjugates significantly suppressed the in vitro growth of HepG2 hepatoma cells with asialoglycoprotein receptors, while less suppression activity was observed for HeLa cells without the receptors. "
05/01/1997 - "Anti-ASGP-R was found in 64 (27.4%) of the 234 patients at titres similar to those found in 18 untreated auto-immune hepatitis patients studied concurrently. "
03/01/1997 - "Virus-induced anti-asialoglycoprotein receptor autoimmunity in experimental hepadnaviral hepatitis."
02/01/1996 - "The therapy of asialoglycoprotein receptor targeting treatment of viral hepatitis has a high specificity. "
09/01/2003 - "Modulation of the outcome and severity of hepadnaviral hepatitis in woodchucks by antibodies to hepatic asialoglycoprotein receptor."
05/01/2000 - "Anti-asialoglycoprotein receptor antibodies are frequently present in the sera of children with auto-immune hepatitis, particularly type 1, The presence of these antibodies is an indirect marker of inflammatory activity."
|4.||Liver Neoplasms (Liver Cancer)
10/01/2011 - "The cytotoxicity, measured by MTT test, indicated that AN and GAL-AN are non-toxic and GAL-DOX-AN is more effective in HepG2 cell killing than that of DOX-AN. As such, our results implied that GAL-AN and GAL-DOX-AN have specific interaction with HepG2 cells via the recognition of GAL and asialoglycoprotein receptor, which renders GAL-AN a promising anticancer drug delivery carrier for liver cancer therapy."
05/09/2011 - "The incubation results of the liver cancer cells, HepG2, with the NPs showed that the NPs are nontoxic and can be recognized by asialoglycoprotein receptors on the surface of HepG2 and then can be internalized. "
05/01/1993 - "In chronic liver disease the asialoglycoprotein receptor concentration significantly correlated with the clinical severity based on the criteria of the Liver Cancer Study Group of Japan (rs = -0.890, p = 0.0001). "
06/01/2011 - "We examine the contribution of the asialoglycoprotein receptor (ASGPR) to the internalization of NAcGal-targeted dendrimers into hepatic cancer cells through a competitive inhibition assay. "
09/24/2014 - "We report the development of a lactobionic acid (LA)-modified multifunctional dendrimer-based carrier system for targeted therapy of liver cancer cells overexpressing asialoglycoprotein receptors. "
|5.||Liver Diseases (Liver Disease)
12/01/2013 - "The results suggest that (99m)Tc-MAMA-DGal may be used as SPECT probes for noninvasive evaluation of asialoglycoprotein receptor-related liver dysfunction. "
04/01/1992 - "In 24 of 25 (96%) of patients without liver disease, the asialoglycoprotein receptor was located on the sinusoidal and, less prominently, the lateral surface of hepatocytes but not the canalicular surface. "
08/01/1991 - "The asialoglycoprotein receptor as target structure in autoimmune liver diseases."
03/01/1991 - "Asialoglycoprotein receptor function in benign liver disease: evaluation with MR imaging."
03/18/1985 - "Hepatic lectin is a highly purifiable, liver-specific, hepatocellular surface component and the anti-lectin assay (which proved sensitive, reliable and easy to perform) will permit further exploration of the role of autoimmune mechanisms in the pathogenesis of various liver diseases."
|5.||Blood Proteins (Serum Proteins)
|1.||Drug Therapy (Chemotherapy)